GMAB - Genmab AS - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

GMAB is currently covered by 8 analysts with an average price target of $29.83. This is a potential upside of $7.96 (36.4%) from yesterday's end of day stock price of $21.87.

Genmab AS's activity chart (see below) currently has 87 price targets and 118 ratings on display. The stock rating distribution of GMAB is 86.96% BUY, 4.35% SELL and 8.7% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 23.36% with an average time for these price targets to be met of 51.63 days.

Highest price target for GMAB is $48, Lowest price target is $27, average price target is $38.

Most recent stock forecast was given by ASTHIKA GOONEWARDENE from TRUIST on 08-Jul-2025.

Currently out of the existing stock ratings of GMAB, 40 are a BUY (86.96%), 2 are a SELL (4.35%), 4 are a HOLD (8.7%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$46

$23.31 (102.73%)

$45

1 months 4 days ago
(08-Jul-2025)

6/15 (40%)

$24.75 (116.47%)

87

Buy

$37

$14.31 (63.07%)

$50

4 months 3 days ago
(09-Apr-2025)

9/47 (19.15%)

$18.17 (96.49%)

131

Buy

$27

$4.31 (19.00%)

$31

5 months 30 days ago
(13-Feb-2025)

4/5 (80%)

$6.08 (29.06%)

173

Buy

$48

$25.31 (111.55%)

$48

9 months 5 days ago
(07-Nov-2024)

1/3 (33.33%)

$24.89 (107.70%)

26

Hold

$31

$8.31 (36.62%)

$31

11 months 1 days ago
(11-Sep-2024)

0/2 (0%)

$4.07 (15.11%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GMAB (Genmab AS) average time for price targets to be met?

On average it took 51.63 days on average for the stock forecasts to be realized with a an average price target met ratio 23.36

Which analyst has the current highest performing score on GMAB (Genmab AS) with a proven track record?

MATTHEW HARRISON

Which analyst has the most public recommendations on GMAB (Genmab AS)?

Matthew Harrison works at MORGAN STANLEY and has 7 price targets and 10 ratings on GMAB

Which analyst is the currently most bullish on GMAB (Genmab AS)?

Etzer Darout with highest potential upside - $25.31

Which analyst is the currently most reserved on GMAB (Genmab AS)?

Matthew Harrison with lowest potential downside - -$0

Genmab AS in the News

Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements

Total Revenue Growth: 19% increase in the first half of 2025. Operating Profit Growth: 56% increase in the first half of 2025. Cash Position: Approximately $3 billion at the end of the first half of 2025. EPKINLY Sales: $211 million in global sales, a 74% year-over-year increase. TIVDAK Sales: $78 million in global sales, a...

Genmab AS earnings beat by $0.15, revenue topped estimates

Investing.com – Genmab AS (NASDAQ: GMAB) reported second quarter EPS of $0.54, $0.15 better than the analyst estimate of $0.39. Revenue for the quarter came in at $925M versus the consensus estimate of $893.39M. Genmab AS’s stock price closed at $22.69. It is up 17.20% in the last 3 months and down -14.15% in the...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?